Boston Scientific Corporation (BSX) — closed signal from July 12, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 10, 2025.
Predicted vs. what happened
What happened
Reached 47% of the predicted growth at its peak, without hitting the target.
The thesis — published July 12, 2025
The share price has eased back to its recent 50-day average, and a low momentum reading often signals a floor. It has already moved above the shorter 20-day average, hinting buyers are stepping in. Farapulse, a new heart treatment, could tap a $9 billion market, and earnings on Jul 24 usually beat expectations. Because some executives sold stock, consider buying a partial stake at $102-104 with a target near $117.
Primary drivers
- Farapulse could give BSX access to a $9B atrial-fib market with strong profits
- Low momentum and climb above recent average price suggest the pullback is ending
- Company beats earnings in 13 of last 14 quarters; July 24 report may lift outlook
- 18% long-term annual growth keeps big investors interested even after insider sales
How it played out
BSX: target was not reached
Lyra published BSX at $103.20 on July 12, 2025, with expected growth of 13%. The thesis pointed to a pullback toward the recent 50-day average, a move back above the shorter 20-day average, Farapulse's possible access to a $9B atrial-fib market, a July 24 earnings setup, and 18% long-term annual growth despite insider sales.
Inside the window, BSX peaked at $109.50 on September 9. That was a 6.1% gain, but it stayed below the $116.62 target. It never got there. By October 10, it ended at $95.41. The thesis partly worked on direction at the peak, but missed the target and finished below the publication price.
What happened during the window
On July 23, 2025, Investors.com reported Boston Scientific second-quarter results and said Farapulse delivered 117% U.S. growth. On July 24, 2025, MarketWatch reported BSX closed at $106.21 after falling 1.44% that day.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.